RU977462C - 13-(1-оксил-2,2,6,6-тетраметилпиперилиденил-4)гидразон рубомицина хлоргидрат с парамагнитным центром, проявляющий противоопухолевую активность, и способ его получения - Google Patents
13-(1-оксил-2,2,6,6-тетраметилпиперилиденил-4)гидразон рубомицина хлоргидрат с парамагнитным центром, проявляющий противоопухолевую активность, и способ его полученияInfo
- Publication number
- RU977462C RU977462C SU802893526A SU2893526A RU977462C RU 977462 C RU977462 C RU 977462C SU 802893526 A SU802893526 A SU 802893526A SU 2893526 A SU2893526 A SU 2893526A RU 977462 C RU977462 C RU 977462C
- Authority
- RU
- Russia
- Prior art keywords
- rubomycin
- hydrazone
- oxyl
- tetramethylpiperylidenyl
- hydrochloride
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims description 13
- 150000007857 hydrazones Chemical class 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 8
- 230000005414 paramagnetic center Effects 0.000 title claims description 6
- ACXCKRZOISAYHH-UHFFFAOYSA-N molecular chlorine hydrate Chemical compound O.ClCl ACXCKRZOISAYHH-UHFFFAOYSA-N 0.000 title 1
- GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 claims description 38
- 229930191933 Rubomycin Natural products 0.000 claims description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- -1 hydrochloride hydrazone Chemical class 0.000 claims description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 10
- 229960000641 zorubicin Drugs 0.000 description 10
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 229960000975 daunorubicin Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 0 CC(*(C1)*c(c(O)c2C(c3c4cccc3O)=O)c1c(O)c2C4=O)NC(CC1C)C*(C)[N+]1O Chemical compound CC(*(C1)*c(c(O)c2C(c3c4cccc3O)=O)c1c(O)c2C4=O)NC(CC1C)C*(C)[N+]1O 0.000 description 2
- 238000004435 EPR spectroscopy Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000007093 Leukemia L1210 Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 241000194106 Bacillus mycoides Species 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 208000000526 Experimental Leukemia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001362 electron spin resonance spectrum Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- FBTUMDXHSRTGRV-BJISBDEGSA-N zorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=NNC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-BJISBDEGSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU802893526A RU977462C (ru) | 1980-03-24 | 1980-03-24 | 13-(1-оксил-2,2,6,6-тетраметилпиперилиденил-4)гидразон рубомицина хлоргидрат с парамагнитным центром, проявляющий противоопухолевую активность, и способ его получения |
| SE8006901A SE449105B (sv) | 1980-03-24 | 1980-10-02 | 13-/1-oxyl-2,2,6,6-tetrametylpiperyldenyl-4/-rubomycinhydrazon hydroklorid samt forfarande for dess framstellning |
| US06/192,964 US4332934A (en) | 1980-03-24 | 1980-10-02 | 13-(1-Oxyl-2,2,6,6-tetramethylpiperylidenyl-4)hydrazone rubomycin hydrochloride with a paramagnetic center and a method of producing same |
| GB8032334A GB2072658B (en) | 1980-03-24 | 1980-10-07 | 13-(1-oxyl-2,2,6,6-tertamethylpiperylidenyl-4) hydrazone rubomycin hydrochloride and a method of producing the same |
| DE3037884A DE3037884C2 (de) | 1980-03-24 | 1980-10-07 | (13-Daunorubicin)-(N-oxyl-2,2,6,6-tetramethylpiperidin-4-on)-azin-hydrochlorid und Verfahren zu seiner Herstellung |
| NLAANVRAGE8005543,A NL182882C (nl) | 1980-03-24 | 1980-10-07 | Rubomycine-derivaat met een anti-tumor-werking, werkwijze voor het bereiden ervan, alsmede farmaceutisch voortbrengsel, dat een dergelijk derivaat bevat. |
| FR8022569A FR2478633A1 (fr) | 1980-03-24 | 1980-10-22 | 13-(1-hydroxy-2,2,6,6-tetramethyl-piperylidenyl-4) hydrazone du chlorhydrate de rubomycine a centre paramagnetique, son procede de preparation, et son application therapeutique |
| IT25669/80A IT1134110B (it) | 1980-03-24 | 1980-10-30 | 13-(1-ossil-2,2,6,6-tetrametil-piperilidenil-4)idrazon rubomicina cloridrato con un centro paramagnetico e metodo per la sua produzione |
| JP158681A JPS56133298A (en) | 1980-03-24 | 1981-01-08 | 13-(1-oxyl-2,2,6,6-tetramethylpiperilidenyl- 4)hydrazone lubomycin hydrochloride having paramagnetic core and manufacture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU802893526A RU977462C (ru) | 1980-03-24 | 1980-03-24 | 13-(1-оксил-2,2,6,6-тетраметилпиперилиденил-4)гидразон рубомицина хлоргидрат с парамагнитным центром, проявляющий противоопухолевую активность, и способ его получения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU977462C true RU977462C (ru) | 1995-06-27 |
Family
ID=20882488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU802893526A RU977462C (ru) | 1980-03-24 | 1980-03-24 | 13-(1-оксил-2,2,6,6-тетраметилпиперилиденил-4)гидразон рубомицина хлоргидрат с парамагнитным центром, проявляющий противоопухолевую активность, и способ его получения |
Country Status (9)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050003008A1 (en) * | 1997-09-23 | 2005-01-06 | Natalya Rapoport | Method of in vivo drug targeting to solid tumors via acoustically triggered drug delivery in polymeric micelles |
| US7910607B2 (en) * | 2006-03-10 | 2011-03-22 | The Trustees Of California State University | Nitroxide free radical synergized antineoplastic agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2235103A1 (en) * | 1973-06-29 | 1975-01-24 | Commissariat Energie Atomique | Marked nitroxide derivatives of saccharides - by reaction of acid nitroxide with halogenated saccharides |
| GB1469430A (en) | 1974-12-24 | 1977-04-06 | Farmaceutici Italia | Daunomycin derivatives |
| US4112217A (en) * | 1977-09-02 | 1978-09-05 | Sri International | Bis-hydrazones of daunomycin and adriamycin |
-
1980
- 1980-03-24 RU SU802893526A patent/RU977462C/ru active
- 1980-10-02 US US06/192,964 patent/US4332934A/en not_active Expired - Lifetime
- 1980-10-02 SE SE8006901A patent/SE449105B/sv not_active IP Right Cessation
- 1980-10-07 GB GB8032334A patent/GB2072658B/en not_active Expired
- 1980-10-07 DE DE3037884A patent/DE3037884C2/de not_active Expired
- 1980-10-07 NL NLAANVRAGE8005543,A patent/NL182882C/xx not_active IP Right Cessation
- 1980-10-22 FR FR8022569A patent/FR2478633A1/fr active Granted
- 1980-10-30 IT IT25669/80A patent/IT1134110B/it active
-
1981
- 1981-01-08 JP JP158681A patent/JPS56133298A/ja active Granted
Non-Patent Citations (2)
| Title |
|---|
| 1. Переводчикова Н.П. Клиническая химиотерапия опухолевых заболеваний. М.: Медицина, 1976. с.37. * |
| 2. Патент Франции N 1578722, кл. C 07D, 1967. * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2478633A1 (fr) | 1981-09-25 |
| SE449105B (sv) | 1987-04-06 |
| JPS6334879B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-07-12 |
| GB2072658A (en) | 1981-10-07 |
| NL182882B (nl) | 1988-01-04 |
| DE3037884C2 (de) | 1983-12-29 |
| NL182882C (nl) | 1988-06-01 |
| FR2478633B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1983-07-22 |
| IT1134110B (it) | 1986-07-24 |
| US4332934A (en) | 1982-06-01 |
| IT8025669A0 (it) | 1980-10-30 |
| JPS56133298A (en) | 1981-10-19 |
| NL8005543A (nl) | 1981-10-16 |
| GB2072658B (en) | 1983-11-02 |
| SE8006901L (sv) | 1981-09-25 |
| DE3037884A1 (de) | 1981-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2074861C1 (ru) | Платиновые фармацевтические средства | |
| EP0219936B1 (en) | Novel platinum complexes | |
| US20230113036A1 (en) | Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance | |
| JP3697210B2 (ja) | 二重ジカルボン酸ジアミノプラチン錯体の抗腫瘍誘導体、その調製方法、それを含む薬剤組成物及びその誘導体の適用方法 | |
| US4511582A (en) | Phenanthrene derivatives | |
| RO113469B1 (ro) | Derivati de indolopirolocarbazol, procedeu pentru prepararea acestora si compozitie farmaceutica continand acesti derivati | |
| WO2012175044A1 (zh) | 用于肿瘤治疗的水溶性铂配合物及其制备方法 | |
| EP0327709A2 (en) | Novel platinum complex, antineoplastic agent containing the same, intermediate therefor, preparation method and use | |
| RU977462C (ru) | 13-(1-оксил-2,2,6,6-тетраметилпиперилиденил-4)гидразон рубомицина хлоргидрат с парамагнитным центром, проявляющий противоопухолевую активность, и способ его получения | |
| KR900008676B1 (ko) | 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로마이신 A유도체 | |
| EP0915895B1 (en) | New salts of anionic complexes of ru(iii), as antimetastatic and antineoplastic agents | |
| US4287205A (en) | Hypotensive and analgesic compounds and compositions and methods for using same | |
| JPS5851959B2 (ja) | プラチナ化合物とその医薬組成物 | |
| SU1565347A3 (ru) | Способ получени производных мочевины, содержащих платину | |
| JPH06199749A (ja) | Ｎ−メチルデアセチルコルヒセインアミド誘導体 | |
| RU2239640C2 (ru) | Производные 5-имино-13-дезокси антрациклина и способ их получения (варианты), фармацевтическая композиция, способ лечения рака, аутоиммунных заболеваний или иммунодефицитных нарушений | |
| RU2171811C2 (ru) | КРИСТАЛЛИЧЕСКИЙ ТРИГИДРОХЛОРИД ДЕОКСИСПЕРГУАЛИНА В β-ФОРМЕ, ОБЛАДАЮЩИЙ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ И СПОСОБ ЕГО ПОЛУЧЕНИЯ | |
| EP0191375A2 (en) | 7-n-aminomethylenemitomycin derivatives, process for production thereof and anti-tumor composition | |
| US4576945A (en) | Hexaalkylmelamine-amino-oxy compounds | |
| JPS6341885B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS6125707B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS58201782A (ja) | 新規１，１０−フエナントロリン誘導体、その製造法および組成物 | |
| KR101560263B1 (ko) | 신규 ４핵 아렌-루테늄 화합물 및 이를 유효성분으로 함유하는 암질환의 치료 또는 예방용 약학조성물 | |
| CA1292470C (en) | 1a 7-substituted derivatives of mitomycin and uses thereof | |
| SU646593A1 (ru) | Комплексные соединени ди/2-хлорэтил/ аминобенз-2,1,3-тиадиазолов с палладием, обладающие противоопухолевой активностью" |